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A B S T R A C T
Background
Symptomatic vitreomacular adhesion (sVMA) is a recognised cause of visual loss and by tradition has been managed by pars plana
vitrectomy (PPV). A less invasive alternative to surgery in some people is enzymatic vitreolysis, using an intravitreal injection of
ocriplasmin.
Objectives
To assess the efficacy and safety of ocriplasmin compared to no treatment, sham or placebo for the treatment of sVMA.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials
Register) (2017, Issue 1), MEDLINE Ovid (1946 to 24 February 2017), Embase Ovid (1947 to 24 February 2017), PubMed (1946
to 24 February 2017), the ISRCTN registry (www.isrctn.com/editAdvancedSearch); searched 24 February 2017, ClinicalTrials.gov (
www.clinicaltrials.gov); searched 24 February 2017 and the World Health Organization (WHO) International Clinical Trials Registry
Platform (ICTRP) (www.who.int/ictrp/search/en); searched 24 February 2017. We did not use any date or language restrictions in the
electronic searches for trials.
Selection criteria
We included randomised controlled trials (RCTs) of people with sVMA. The intervention was intravitreal ocriplasmin 125µg injection,
and this was compared to placebo or sham injection (control). Placebo was defined as a single intravitreal injection of 0.10 mL placebo
with identical drug vehicle diluted with saline. A sham injection was defined as the syringe hub or blunt needle touching the conjunctiva
to simulate an injection.
Data collection and analysis
Two authors independently selected relevant trials, assessed methodological quality and extracted data. We graded the certainty of the
evidence using the GRADE approach.
Main results
This review included four RCTs conducted in Europe and the USA with a total of 932 eyes of 932 participants. Participants were 18 to
97 years of age, with evidence of focal vitreomacular adhesion (VMA) on optical coherence tomography (OCT) imaging, with a best
corrected visual acuity (BCVA) of 20/25 or worse in the study eye and 20/400 or better in the fellow eye. The interventions compared
were intravitreal ocriplasmin versus sham (two RCTs) or placebo (two RCTs) injection. Both sham and placebo injection were classified
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as the control group. The main outcome measures were assessed at 28 days and six months. Overall, we judged the studies to have a
low or unclear risk of bias. All four RCTs were sponsored by the manufacturers of ocriplasmin.
Compared with control, ocriplasmin treatment was more likely to result in VMA release within 28 days (risk ratio (RR) 3.46, 95%
confidence interval (CI) 2.00 to 6.00; 859 eyes, 4 RCTs, high-certainty evidence). Approximately 97/1000 eyes will have VMA release
within 28 days without treatment. An additional 237 eyes will have VMA release within 28 days for every 1000 eyes treated with
ocriplasmin (95% CI 96 more to 482 more).
Treatment with ocriplasmin was also more likely to result in macular hole closure (RR 2.87, 95% CI 1.50 to 5.51; 229 eyes, 3 RCTs,
high-certainty evidence). Approximately 123/1000 eyes with macular holes will have closure with no treatment. An additional 231
eyes will have macular hole closure for every 1000 eyes treated with ocriplasmin (95% CI 62 more to 556 more).
Eyes receiving ocriplasmin were also more likely to have complete posterior vitreous detachment (PVD) within 28 days (RR 2.94, 95%
CI 1.39 to 6.24; 689 eyes, 3 RCTs, high-certainty evidence). Approximately 40/1000 eyes will have complete PVD within 28 days
without treatment. An additional 78 eyes will have complete PVD within 28 days for every 1000 eyes treated with ocriplasmin (95%
CI 16 more to 210 more).
Eyes receiving ocriplasmin were more likely to achieve 3-line or greater improvement in BCVA at six months (RR 1.95, 95% CI 1.07
to 3.53; 674 eyes, 3 RCTs, moderate-certainty evidence). Approximately 61/1000 eyes will have a 3-line or greater improvement in
BCVA at six months without treatment. An additional 58 eyes will have 3-line or greater improvement in BCVA at six months for
every 1000 eyes treated with ocriplasmin (95% CI 9 more to 154 more).
Receiving ocriplasmin also reduced the requirement for vitrectomy at six months (RR 0.67, 95% CI 0.50 to 0.91; 689 eyes, 3 RCTs,
moderate-certainty evidence). Approximately 265/1000 eyes will require vitrectomy at six months without treatment and 87 fewer eyes
will require vitrectomy for every 1000 eyes treated with ocriplasmin (95% CI 24 fewer to 132 fewer).
Treatment with ocriplasmin resulted in a greater improvement in validated Visual Function Questionnaire form score at six months
(mean improvement difference 2.7 points, 95% CI 0.8 to 4.6; 652 eyes, 2 RCTs, moderate-certainty evidence).
Eyes receiving ocriplasmin were more likely to have an adverse event (RR 1.22, 95% CI 1.09 to 1.37, 909 eyes, 4 RCTs, moderate-
certainty evidence). Approximately 571/1000 eyes will have an adverse event with sham or placebo injection and 106 more eyes will
have an adverse event for every 1000 eyes treated with ocriplasmin (95% CI 52 more to 212 more).
Authors’ conclusions
Evidence from a limited number of RCTs suggests that ocriplasmin is useful in the treatment of sVMA. However, up to 20% of eyes
treated with ocriplasmin will still require additional treatment with PPV within six months. There were more ocular adverse events in
eyes treated with ocriplasmin than control (sham or placebo injection) treatment. Many of these adverse events, particularly vitreous
floaters and photopsia, are known to be associated with posterior vitreous detachment. At present however, there is minimal published
long-term safety data on eyes treated with ocriplasmin. Further large RCTs comparing ocriplasmin with other management options for
sVMA would be beneficial.
P L A I N L A N G U A G E S U M M A R Y
Ocriplasmin for symptomatic vitreomacular adhesion
What is the aim of this review?
The aim of this Cochrane Review was to find out how well ocriplasmin works in the treatment of symptomatic vitreomacular adhesion
(sVMA). Cochrane Review authors collected and analysed all relevant studies to answer this question and found four studies.
Key messages
People with sVMA treated with ocriplasmin have an increased chance of release of sVMA and improved vision compared with people
who are not treatedwith ocriplasmin (high-certainty evidence). They are also probably less likely to require surgery, but one in five people
with sVMA treated with ocriplasmin will probably still require surgery at a later date to treat sVMA (moderate-certainty evidence).
What was studied in the review?
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With age, the gel-like substance (vitreous) that fills the eye begins to pull away from the back of the eye (retina). Sometimes the vitreous
remains attached to the retina and causes damage to the retina as it pulls away, leading to visual loss. This is known as symptomatic
vitreomacular adhesion or sVMA. sVMA includes two related conditions, vitreomacular traction and macular hole.
The standard treatment for sVMA is surgery. Ocriplasmin is an alternative, less invasive, treatment. This is an enzyme that can be
injected directly into the eye to release the vitreous from the retina.
What are the main results of the review?
Cochrane Review authors found four studies that compared ocriplasmin with control (sham or placebo treatment) for the treatment
of sVMA. All four studies were sponsored by the manufacturers of ocriplasmin.
The review showed that:
• ocriplasmin increases the chance of sVMA resolution compared with no treatment (high-certainty evidence);
• people with sVMA treated with ocriplasmin have improved vision compared with people who are not treated with ocriplasmin (high-
certainty evidence);
• treatmentwith ocriplasmin probably reduces the requirement for surgery, but approximately one in five people treatedwith ocriplasmin
may require further surgery at a later date (moderate-certainty evidence);
• there were more ocular adverse events in eyes treated with ocriplasmin than control (sham or placebo injection) treatment.
How up-to-date is this review?
Cochrane Review authors searched for studies that had been published up to 24 February 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Ocriplasmin injection compared with control for symptomatic vitreomacular adhesion
Patient or population: people with symptomatic vitreomacular adhesion
Settings: eye hospital
Intervention: ocriplasmin inject ion
Comparison: sham or placebo inject ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of eyes
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Sham or placebo injec-
tion
Ocriplasmin injection
Complete release of
vitreous adhesion
Follow-up: 28 days
97 per 1000 334 per 1000
(193 to 579)
RR 3.46
(2.00 to 6.00)
859
(4 studies)
⊕⊕⊕⊕
High
-
Closure of macular
hole
Follow-up: 28 days to
24 months
123 per 1000 354 per 1000
(185 to 679)
RR 2.87
(1.50 to 5.51)
229
(3 studies)
⊕⊕⊕⊕
High
-
Complete posterior vit-
reous detachment
Follow-up: 28 days
40 per 1000 118 per 1000
(56 to 250)
RR 2.94
(1.39 to 6.24)
689
(3 studies)
⊕⊕⊕⊕
High
-
3- line or greater im-
provement in best-cor-
rected visual acuity
Follow-up: 6 months
61 per 1000 119 per 1000
(70 to 215)
RR 1.95
(1.07 to 3.53)
674
(3 studies)
⊕⊕⊕©
Moderatea
-
Requirement for vitrec-
tomy
Follow-up: 6 months
265 per 1000 178 per 1000
(133 to 241)
RR 0.67
(0.50 to 0.91)
689
(3 studies)
⊕⊕⊕©
Moderatea
-
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Mean change in val-
idated visual function
questionnaire score
from baseline
Score ranges f rom 0 to
100, higher scores are
better visual funct ion
Follow-up: 6 months
Mean change in NEI-
VFQ score was 0.7
NEI-VFQ score was 2.7
higher (0.8 higher to 4.
6 higher)
- 652
(2 studies)
⊕⊕⊕©
Moderatea
-
Any ocular adverse
event
Follow-up: 6 months
571 per 1000 697 per 1000
(623 to 783)
RR 1.22
(1.09 to 1.37)
909
(4 studies)
⊕⊕⊕©
Moderatea
-
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; NEI-VFQ: National Eye Inst itute Visual Funct ion Quest ionnaire; RCT: randomised controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High-certainty: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate-certainty: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low-certainty: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low-certainty: We are very uncertain about the est imate.
aDowngraded one level for imprecision (-1).
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B A C K G R O U N D
Description of the condition
In healthy eyes, the posterior vitreous face lies in contact with the
internal limitingmembrane (ILM)of the retinawith various points
of stronger adhesion such as the macula, vasculature and optic
disc. Over time, the structure of the vitreous liquefies in a process
known as synchysis, with reduction in the adhesive forces between
vitreous and ILM. This often results in the vitreous gel detaching
from all parts of the retina, except at the vitreous base anteriorly, in
a normal process known as posterior vitreous detachment (PVD)
(Foos 1982). The process usually starts with focal detachment in
the perifovea of the superior quadrant and then extends slowly for
years until eventually resulting in a complete PVD with release of
vitreopapillary adhesion (Ito 2003; Johnson 2010; Uchino 2001).
However, in certain cases, incomplete PVDmay occur, leaving the
vitreous in contact with the macula or optic disc, or both.
Although, anatomically, vitreomacular adhesion (VMA)may refer
to a normal asymptomatic state, clinically, the term is used when
VMA occurs in the context of an incomplete PVD. There is a
spectrum of VMA associated with incomplete PVD, which ranges
from asymptomatic, non-tractional VMA to extensive distortion
of the retinal structure due to vitreomacular traction (VMT)which
may result in loss of visual function. These distinctions tend to
be based on optical coherence tomography (OCT), sometimes
in reference to defined photographic standards (Simpson 2012).
However, it is important to note that the OCT changes, which
may include retinal thickening and intraretinal oedema, do not
always correlate with visual function and symptoms.
Symptomatic vitreomacular adhesion (sVMA) is defined as visual
loss secondary to foveal damage caused by abnormal VMT. sVMA
includes isolated VMT, impending macular hole (MH) and MH
with persisting vitreous attachment (Jackson 2013a). Impending
MH is often grouped with VMT. Epiretinal membrane (ERM)
often coexists with sVMA. It is possible that VMA influences the
clinical course of, or may be associated with, other diseases such
as diabetic macular oedema, retinal vein occlusion or neovascu-
lar age-related macular degeneration, although the data are some-
times conflicting (Jackson 2013a; Jackson 2013b; Nomura 2014;
Simpson 2012; Terao 2014; Waldstein 2014; Yoon 2014). Whilst
there may be an association between sVMA and these other dis-
eases, it is not certain that this is causal (Simpson 2012). Conse-
quently, it is difficult to define the prevalence of sVMA. One study
reported that VMA may occur in isolation or in association with
other eye disease in approximately 1.5%of the population (Jackson
2013a). However, the majority of these cases occurred alongside
ERM, and thus the VMA may not be responsible for visual loss.
Excluding cases associated with ERM reduced the prevalence to
0.35% in the same population-based study; however, this figure
also included caseswith other diseases, such aswet age-relatedmac-
ular degeneration and diabetic macular oedema (Jackson 2013a).
If only cases of isolated VMA/VMT with or without MH were
considered, then the prevalence of sVMA was 171.5 per 100,000
population (Jackson 2013a).
The natural history of sVMA varies. sVMAmay spontaneously re-
solve, with detachment of the posterior vitreous face from the ILM
(Steel 2013). One study of 53 eyes showed a complete PVD oc-
curred in 11% of eyes over 60 months’ follow-up (Hikichi 1995).
Weinard and colleagues reported that approximately 10% of cases
of VMT syndrome resolve spontaneously (Weinard 2009). Other
studies have found spontaneous resolution in 17% to 35% of cases
with VMT (Almeida 2015; Theodossiadis 2014; Zhang 2015).
Eyes with VMT and isolated inner retinal distortion, as well as
those receiving vitreous injections, have an increased likelihood of
VMTrelease (Almeida 2015). Poor prognostic indicators for spon-
taneous release include the presence of ERM and large horizon-
tal adhesion diameter (Haller 2015; Jackson 2016; Theodossiadis
2014; Zhang 2015). It has been shown that many, if not most,
MHs result from persistent VMTwhich either fully detaches from
the retina causing an MH, or remains attached at the edge of the
hole (Chauhan 2000; Gass 1988; Gaudric 1999; La Cour 2002;
Tanner 2001).
Description of the intervention
Treatment strategies for VMA vary depending on disease sever-
ity. Asymptomatic VMT can be observed, since separation of the
posterior vitreous face may occur spontaneously and without se-
quelae. However, a longer duration of VMT may lead to loss of
vision and possibly lower efficacy of any subsequent intervention,
and therefore treatment is often considered if symptoms are sig-
nificant or visual acuity is reduced (Hikichi 1995; Melberg 1995;
Sonmez 2008). If VMT progresses to MH then intervention is
usually advised, and an evolving VMT/impending MH may like-
wise necessitate intervention.
If intervention is considered for sVMA, various strategies may be
considered. Traditionally, pars plana vitrectomy (PPV) is the stan-
dard approach for VMT or MH (Steel 2013). Small uncontrolled
studies reported that an intravitreal gas bubble can pneumatically
release VMT, without the need for PPV, with success rates varying
from 71% to 95% (Chan 1995; Mori 2007; Rodrigues 2013).
Pharmacological vitreolysis has been investigated as an alterna-
tive treatment for VMT, and for MH with persisting VMA (Benz
2010; De Smet 2009; Stalmans 2010; Stalmans 2012). Autolo-
gous plasmin, an enzyme that breaks down the laminin and fi-
bronectin bonds maintaining vitreous adhesion, has been used
perioperatively to induce a PVD during vitrectomy (Margherio
1998; Sakuma 2006; Williams 2001). However, autologous plas-
min is not suited to the treatment of VMT due to its autolytic
instability (Gandorfer 2008). Based on autologous plasmin, a re-
combinant DNA molecule, initially referred to as microplasmin,
and more recently ocriplasmin (Jetrea; ThromboGenics, Leuven,
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Belgium), was developed to provide the same catalytic properties
but with greater stability.
Ocriplasmin is administered as a single intravitreal injection of 125
µg in 0.1 mL. It has marketing authorisation for the treatment of
VMT, including when associated withMHof diameter of 400µm
or less (SmPC 2013). In the UK, the National Institute for Health
and Care Excellence (NICE) supports the use of ocriplasmin for
adults with VMT causing severe sight problems or a macula hole
up to 400 µm, in the absence of ERM (NICE 2013).
How the intervention might work
Ocriplasmin is a proteolytic enzyme which targets laminin and
fibronectin, both of which are important structural components of
the interface between the vitreous and the retina. It is a truncated
form of the human serine protease plasmin which functions in a
two-stagemechanism; liquefactionof the vitreous and vitreoretinal
separation (Kuppermann 2012).
Why it is important to do this review
Ocriplasmin has marketing authorisation in Europe and the USA
and is the only licensed, non-surgical treatment for sVMA. MH
is the second most common indication for PPV, and both MH
and VMT can cause substantial visual problems (Jackson 2013c).
This review is important as it assessed the efficacy and safety of
ocriplasmin treatment.
O B J E C T I V E S
To assess the efficacy and safety of ocriplasmin compared to no
treatment, sham or placebo for the treatment of sVMA.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) only.
Types of participants
We included participants with a diagnosis of sVMA, including
VMT and MH of 400 µm or less with persisting VMA. There
were no restrictions with regards to gender, age or ethnicity.
Types of interventions
We included any RCT in which intravitreal ocriplasmin was com-
pared to no treatment, sham injection or placebo.
Types of outcome measures
Primary outcomes
• Proportion of eyes with complete release of vitreous
adhesion as determined by analysis of OCT images captured 28
days after ocriplasmin, sham or placebo treatment.
Secondary outcomes
• Proportion of eyes with closure of MH as determined by
analysis of OCT images captured 28 days after ocriplasmin,
sham or placebo treatment.
• Proportion of eyes with complete PVD as measured by
clinical examination or B-scan ultrasonography 28 days after
ocriplasmin, sham or placebo treatment.
• Proportion of eyes with 3-line or greater improvement in
best corrected visual acuity (BCVA) from baseline, measured
using Early Treatment Diabetic Retinopathy Study (ETDRS) at
4 m or Snellen chart, at six months after ocriplasmin, sham or
placebo treatment.
• Proportion of eyes requiring PPV within six months of
ocriplasmin, sham or placebo treatment (as recommended by the
investigator if the underlying condition deteriorated, BCVA
worsened by more than 2 lines on ETDRS or Snellen chart, or if
the underlying condition had not improved within 28 days after
treatment).
• Mean change in validated Visual Function Questionnaire
(VFQ) score from baseline, measured at six months after
ocriplasmin, sham or placebo treatment.
Safety outcomes
• Description of ocular adverse events and serious adverse
events, and any non-ocular serious adverse events attributed to
ocriplasmin or no treatment/sham/placebo.
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist conducted
systematic searches in the following databases for randomised con-
trolled trial and controlled clinical trials. There were no language
or publication year restrictions. The date of the search was 24
February 2017.
7Ocriplasmin for symptomatic vitreomacular adhesion (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 1) (which contains the Cochrane Eyes
and Vision Trials Register) in the Cochrane Library (searched 24
February 2017) (Appendix 1);
• MEDLINE Ovid (1946 to 24 February 2017) (Appendix
2);
• Embase Ovid (1980 to 24 February 2017) (Appendix 3);
• PubMed (1946 to 24 February 2017) (Appendix 4);
• ISRCTN registry (www.isrctn.com/editAdvancedSearch;
searched 24 February 2017) (Appendix 5);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov; searched 24 February
2017) (Appendix 6);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (www.who.int/ictrp; searched
24 February 2017) (Appendix 7).
Searching other resources
We searched the reference lists of included studies for other pos-
sible studies. We did not search proceedings from conferences
specifically, because such RCTs presented at these meetings were
searched by Cochrane Eyes and Vision and included in CEN-
TRAL.
Data collection and analysis
Selection of studies
Three authors (JN, VK and TJ) independently assessed the results
identified by the searches and classified each record as either possi-
bly relevant or definitely not relevant. We then obtained full-text
copies of all possibly relevant records, and three authors (JN, VK
and TJ) classified them as definitely include, unsure or definitely
exclude based on the criteria for inclusion. In the event of any dif-
ficulty in classification due to lack of clarity or data, we contacted
study investigators for further information. All contacted authors
responded to our requests. We resolved discrepancies by consensus
following discussion between authors (JN, VK and TJ) and docu-
mented this in the review. All excluded records were documented.
Data extraction and management
Two authors (JN and VK) independently extracted trial data for
the primary and secondary outcomes onto paper data extraction
forms developed by Cochrane Eyes and Vision. Subsequently, data
were transcribed into Review Manager 5 (RevMan 2014) by one
author (JN) and verified by a second author (VK). Any discrep-
ancies were resolved by consensus between authors (JN, VK and
TJ) and documented in the review.
We collected the following information on study characteristics
(see Appendix 8):
• study design: parallel group RCT/within-person RCT/one
or both eyes reported;
• participants: country, total number of participants, age, sex,
inclusion and exclusion criteria;
• intervention and comparator details: including number of
people (eyes) randomised to each group;
• primary and secondary outcomes as measured and reported
in the trials, adverse events;
• length of follow-up;
• date study conducted;
• funding and conflicts of interest.
We extracted the following data from each included study for
intervention and comparator groups separately:
• number of events and number of participants for outcome
data collected for dichotomous variables (release of vitreous
adhesion at 28 days, closure of MH at 28 days and complete
PVD at 28 days);
• mean, standard deviation and number of participants for
outcome data measured for continuous variables (change in
BCVA at six months and change in validated VFQ at six
months). To compare visual acuity across studies, the mean
BCVA was converted to logarithm of the minimum angle of
resolution units (logMAR). Counting fingers vision was assigned
a logMAR acuity of 1.6, hand movements 1.9, light perception
2.2 and no light perception 2.5 (Westheimer 1979). The default
VFQ assessed was the National Eye Institute Visual Functioning
Questionnaire - 25 (NEI-VFQ25).
We collected evidence of harm from RCTs only.
Assessment of risk of bias in included studies
Two authors (JN and VK) independently assessed the included
trials for bias using the methods and grades described in Chapter
8 of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011a). We assessed the following: methods of sequence
generation used for randomisation; allocation concealment; mask-
ing (blinding) of outcome assessors; masking of participants and
personnel; incomplete outcome data; selective outcome reporting;
other bias. We considered the use, or not, of independent masked
OCT image analysis assessors in the assessment of bias. We then
classified each item as ’low,’ ’high’ or ’unclear’ risk of bias.
Measures of treatment effect
We presented dichotomous data as risk ratios (RR) with 95%
confidence intervals (CI);
• Primary outcome:
◦ resolution of VMA.
• Secondary outcomes:
◦ closure of MH;
◦ complete PVD;
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◦ proportion of eyes with 3-line or greater gain in
BCVA;
◦ requirement for PPV.
We presented continuous data as mean differences with 95% CIs:
• change in validated VFQ measure.
Unit of analysis issues
Trials randomised one or both eyes to the intervention or com-
parator. If people were randomly allocated to treatment but only
one eye per person was included in the trial then there was no unit
of analysis issue. In these cases, we documented how the eye was
selected and if this was done before randomisation. If people were
randomly allocated to treatment but both eyes were included and
reported, we planned to analyse as ’clustered data,’ that is, adjust
for within-person correlation. If the study was a within-person
study, that is, one eye was randomly allocated to intervention and
the other eye received the comparator, then we planned to analyse
as paired data. We planned to contact the trial investigators for
further information to do this if necessary.
Dealing with missing data
In the event of missing trial outcome data, we contacted the au-
thors of the trial to understand why the data were missing. If no
response was received within four weeks, we used the informa-
tion provided in the published articles. Missing data were han-
dled in accordance with the guidelines given in Chapter 16 of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011b). We planned to perform sensitivity analyses on the impact
of missing data and comment on the findings in the discussion of
the review.
Assessment of heterogeneity
We assessed heterogeneity and inconsistency among trials statisti-
cally using an I2 value (> 50%) to assess if variability in effect was
due to sampling error. We also planned to assess diversity among
studies by reviewing participant characteristics and trial method-
ology.
Assessment of reporting biases
We assessed selective outcome reporting by comparing intended
outcomes in published protocols, published methods papers and
clinical trial registries to reported outcomes in the results sections
of trial reports. If there were 10 or more eligible RCTs, we planned
to use a funnel plot to assess for study-reporting bias.
Data synthesis
If there were three or fewer eligible RCTs then we planned to use
a fixed-effect model for the meta-analyses. If there were more than
three included trials, we planned to use a random-effects model
instead. If we had evidence of high heterogeneity (e.g. I2 > 50%),
it would not be sensible to pool the data from different trials; in
which case, we planned to do a narrative summary of the results.
Subgroup analysis and investigation of heterogeneity
If trials demonstrated clinical heterogeneity and sufficient data
were available, including age (< 65 years, 65 years and over), pres-
ence of ERM, size of adhesion (less than 1500 µm, 1500 µm or
greater) and sVMA subtype (isolated VMT, andMHwith persist-
ing vitreous attachment), we planned to perform subgroup anal-
yses for the primary outcome.
Sensitivity analysis
We planned to conduct one sensitivity analysis, excluding studies
that were at high risk of bias in one or more domains.
’Summary of findings’ table
We prepared a ’Summary of findings’ table for the following out-
comes:
• resolution of VMA at 28 days;
• complete PVD at 28 days;
• closure of MH at 28 days;
• proportion gaining 3-line or greater improvement in BCVA
at six months;
• requirement of PPV at six months;
• change in validated VFQ measure at six months;
• adverse and serious adverse events.
Two authors (JN and VK) independently graded the overall cer-
tainty of the evidence for each outcome using the GRADEWork-
ing Group classification (GRADEpro 2014).
R E S U L T S
Description of studies
Results of the search
The electronic searches yielded 418 records (Figure 1). The
Cochrane Information Specialist scanned the search results, re-
moved 136 duplicates and then removed 123 references which
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were irrelevant to the scope of the review. We screened the re-
maining 159 reports and obtained 14 full-text reports for fur-
ther assessment. We included five reports of four RCTs, three re-
ports (Haller 2015; Stalmans 2012; Varma 2015) analysed sep-
arate outcomes from the same two RCTs (TG-MV-006 2012;
TG-MV-007 2012).We excluded nine reports of nine studies (see
Characteristics of excluded studies for details). We did not identify
any ongoing studies from our searches of clinical trials registries.
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Figure 1. Study flow diagram.
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Included studies
The following is a summary of the characteristics of the four RCTs
that met the review inclusion criteria (MIVI-IIT 2010; OASIS
2016; TG-MV-006 2012; TG-MV-007 2012). All data were ini-
tially obtained from published literature, then verified for discrep-
ancies using the clinical trials registries described in the Methods
section. See theCharacteristics of included studies table for further
information.
Types of participants
The four RCTs included enrolled 932 participants (932 eyes).
All participants received individually randomised, parallel group
treatment to a single eye. The age range of all included partici-
pants was 18 to 97 years. All included participants had evidence
of focal VMA on OCT, BCVA of 20/25 or worse in the study
eye and 20/400 or better in the fellow eye (ETDRS acuity chart).
Exclusion criteria were: active proliferative diabetic retinopathy,
high myopia (axial length greater than 26 mm or more than -8
dioptres), previous vitrectomy or uncontrolled glaucoma, previous
intravitreal injections within the past three months in the study
eye, intraocular surgery or laser photocoagulation within the past
three months in the study eye or rhegmatogenous retinal detach-
ment in either eye. Additional exclusion criteria in TG-MV-007
2012 were: neovascular age-related macular degeneration, retinal
vascular occlusion, aphakia, MH greater than 400 µm in diam-
eter, vitreous opacification or lenticular or zonular instability. In
OASIS 2016, eyes with an ERM were also excluded from enrol-
ment.
Types of interventions
MIVI-IIT 2010 compared a single injection of ocriplasmin 75µg,
ocriplasmin 125 µg or ocriplasmin 175 µg with sham injection
(conjunctiva touched with a blunt needle to simulate an injection)
to establish the optimal dose. A fourth cohort of participants un-
derwent an initial injection of ocriplasmin 125 µg, but also a re-
peat injection at four and eight weeks if VMA was still present on
OCT. Therefore, only data from participants receiving ocriplas-
min 125 µg in this study were extracted and pooled for analy-
sis. TG-MV-006 2012 and TG-MV-007 2012 both compared a
single injection of ocriplasmin 125 µg with placebo injection (of
the same vehicle used in the ocriplasmin injection). OASIS 2016
compared a single injection of ocriplasmin 125 µg with sham in-
jection (syringe hub pressed into conjunctiva to simulate an injec-
tion).
Types of outcome measures
All four studies reported data for some of our primary and sec-
ondary outcome measures. No trial reported data for every out-
come measure. Two trial reports (OASIS 2016; Varma 2015) pro-
vided data on participant-reported outcome measures using the
NEI-VFQ25.
Data synthesis, subgroup and sensitivity analyses
As the search identified four trials, we used a random-effects model
(seeData synthesis). As there was no evidence of significant hetero-
geneity for the primary outcomes (I2 < 50%), we pooled data and
performed no subgroup analyses of the primary outcome. Since no
studies had a high risk of bias in any domain, we did not conduct
a sensitivity analysis.
Excluded studies
We excluded nine articles after reviewing full-text copies (Benz
2010; De Smet 2009; Dugel 2015; Elbendary 2011; Lanzetta
2014a; Lanzetta 2014b; Lescrauwaet 2016; Jackson 2017; Novack
2015). See Characteristics of excluded studies table for details.
Risk of bias in included studies
See Figure 2 and Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
MIVI-IIT 2010 did not describe the method of sequence gen-
eration, and provided insufficient information to also assess al-
location concealment (Stalmans 2010). TG-MV-006 2012 and
TG-MV-007 2012 clearly described randomisation and alloca-
tion concealment, which as a centralised telephone-based system
with blocks of treatment assigned to sites (Haller 2015; Stalmans
2012; Varma 2015). OASIS 2016 clearly described the method of
randomisation, which used a centralised interactive voice response
system.
Blinding
Two trials adequately masked participants and investigators (TG-
MV-006 2012; TG-MV-007 2012). However, two trials did not
mask investigators to sham injections (MIVI-IIT 2010; OASIS
2016), which may have induced a different sensation to a true
injection. The risk of performance bias was graded as unclear for
both studies.
Incomplete outcome data
We graded risk of bias as low in one study (MIVI-IIT 2010),
and unclear in the other three studies (OASIS 2016; TG-MV-
006 2012; TG-MV-007 2012). Unclear risk was due to losses to
follow-up not being reported and being unequal in different study
groups. In addition, OASIS 2016 randomised 200 participants,
but 50 participants were later found to be incorrectly enrolled by
the central reading centre for a variety of reasons including MH
greater than 400 µm, presence of ERM or no VMA at baseline. A
subgroup analysis of this smaller cohort of participants, who met
the inclusion and exclusion criteria, was performed, but only on
outcome data for VMA release.
One trial reported a dilution error, which resulted in an extra
participant treated in the ocriplasmin 125 µg cohort and one less
participant in the ocriplasmin 175 µg cohort (MIVI-IIT 2010).
Selective reporting
All studies reported on all prespecified primary and secondary
outcomes (MIVI-IIT 2010; OASIS 2016; TG-MV-006 2012;
TG-MV-007 2012).
Other potential sources of bias
Two studies reported a baseline imbalance between study groups as
pseudophakia was more common in the ocriplasmin group than in
the placebo group and there were more women in the ocriplasmin
group than in the placebo group (TG-MV-006 2012; TG-MV-
007 2012). Therefore, this was at unclear risk of bias.
Effects of interventions
See: Summary of findings for the main comparison
Ocriplasmin injection compared with control for symptomatic
vitreomacular adhesion
See Summary of findings for the main comparison.
1. Proportion of eyes with complete release of
vitreous adhesion
All four RCTs provided data for proportion of eyes with complete
release of vitreous adhesion as determined by analysis of OCT im-
ages captured 28days after ocriplasmin, shamor placebo treatment
(MIVI-IIT 2010; OASIS 2016; TG-MV-006 2012; TG-MV-007
2012). After excluding participants with protocol violations from
OASIS 2016, analysis of the pooled data showed higher complete
release of vitreous adhesion in the ocriplasmin group compared
with control (placebo or sham) treatment (RR 3.46, 95% CI 2.00
to 6.00; 859 eyes; 4 studies; high-certainty evidence; Analysis 1.1).
A total of 97/1000 eyes had VMA release within 28 days with-
out treatment. An additional 237 eyes had VMA release within
28 days for every 1000 eyes treated with ocriplasmin (95% CI 96
more to 482 more).
2. Proportion of eyes with closure of macular hole
Three studies provided data for proportion of eyes with closure of
MH as determined by analysis of OCT images captured 28 days
after ocriplasmin, sham or placebo treatment (OASIS 2016; TG-
MV-006 2012; TG-MV-007 2012); data from MIVI-IIT 2010
could not be included in this analysis as the original paper did
not provide a breakdown of the ocriplasmin doses used to treat
MH. OASIS 2016 measured MH closure at three months and
the closure rate remained the same to the end of the study at 24
months. After excluding 14 participants incorrectly enrolled in
OASIS 2016 due to MH being greater than 400 µm, analysis of
the pooled data showed higher closure of MH in the ocriplasmin
group compared with control (placebo or sham) treatment (RR
2.87, 95% CI 1.50 to 5.51; 229 eyes; 3 studies; high-certainty
evidence; Analysis 1.2). A total of 123/1000 eyes with MHs had
closure with no treatment. An additional 231 eyes hadMHclosure
for every 1000 eyes treated with ocriplasmin (95% CI 62 more to
556 more).
3. Proportion of eyes with complete posterior
vitreous detachment
Three studies provided data for proportion of eyes with com-
plete PVD as measured by clinical examination or B-scan ultra-
sonography 28 days after ocriplasmin, sham or placebo treatment
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(MIVI-IIT 2010; TG-MV-006 2012; TG-MV-007 2012). Anal-
ysis revealed a higher incidence of complete PVD at 28 days in
eyes treated with ocriplasmin compared with control (placebo or
sham) treatment (RR 2.94, 95% CI 1.39 to 6.24; 689 eyes; 3
studies; high-certainty evidence; Analysis 1.3). A total of 40/1000
eyes had complete PVDwithin 28 days without treatment. An ad-
ditional 78 eyes had complete PVDwithin 28 days for every 1000
eyes treated with ocriplasmin (95% CI 16 more to 210 more).
4. Proportion of eyes with 3-line or greater
improvement in best corrected visual acuity
Three studies provided data for proportion of eyes with 3-line
or greater improvement in BCVA measured using the ETDRS
scale, at six months after ocriplasmin, sham or placebo treatment
(MIVI-IIT 2010; TG-MV-006 2012; TG-MV-007 2012). Due
to separate outcomes reported for eyes with and without full-
thickness MH, and large numbers of participants not meeting
eligibility criteria, data were not included from OASIS 2016. Eyes
that had undergone PPV inMIVI-IIT 2010 during this six-month
period were also excluded. Analysis of the pooled data revealed
that eyes treated with ocriplasmin without PPV were more likely
to achieve 3-line or greater improvement in BCVA than control
(sham or placebo) eyes (RR 1.95, 95% CI 1.07 to 3.53; 674 eyes;
3 studies; moderate-certainty evidence; Analysis 1.4). A total of
61/1000 eyes had 3-line or greater improvement in BCVA at six
months without treatment. An additional 58 eyes had 3-line or
greater improvement in BCVA at six months for every 1000 eyes
treated with ocriplasmin (95% CI 9 more to 154 more).
5. Proportion of eyes requiring vitrectomy within six
months of ocriplasmin, sham or placebo treatment
Three studies provided data for proportion of eyes requiring vitrec-
tomy (MIVI-IIT 2010; TG-MV-006 2012; TG-MV-007 2012).
All three RCTs defined the requirement for vitrectomy as “rec-
ommended by the investigator if the underlying condition dete-
riorated, BCVA worsened by more than two lines on ETDRS or
Snellen chart, or if the underlying condition had not improved
within 28 days after treatment.” Due to separate outcomes re-
ported for eyes with and without full-thickness MH, and large
numbers of participants not meeting eligibility criteria, data were
not included fromOASIS 2016. Analysis revealed a lower require-
ment for vitrectomy in eyes treated with ocriplasmin compared
with control (placebo or sham) treatment (RR 0.67, 95% CI 0.50
to 0.91; 689 eyes; 3 studies; moderate-certainty evidence; Analysis
1.5). A total of 265/1000 eyes required vitrectomy at six months
without treatment and 87 fewer eyes required vitrectomy for ev-
ery 1000 eyes treated with ocriplasmin (95% CI 24 fewer to 132
fewer).
6. Mean change in validated Visual Function
Questionnaire score from baseline measured at six
months after ocriplasmin, sham or placebo treatment
One trial reported data for mean change in validated VFQ score
from baseline (Varma 2015), which analysed pooled participant-
reported visual functionoutcomes forTG-MV-006 2012 andTG-
MV-007 2012. In all eyes across both studies, mean increases in
the composite NEI-VFQ25 score at six months frombaseline were
greater in eyes treated with ocriplasmin (464 eyes) than placebo
(188 eyes) (mean change: 3.4 with ocriplasmin versus 0.7 with
placebo; P = 0.005). We calculated the mean difference as 2.7
(95% CI 0.8 to 4.6). Visual function data was also reported in
OASIS 2016, but this was not reported for the subgroup who
met the inclusion and exclusion criteria following central reading
centre analysis.
7. Adverse effects
Due to inconsistencies between the studies and differences in con-
trol groups (placebo injection versus sham injection), we did not
perform a pooled analysis of adverse events. Instead, a descrip-
tive account of the types of ocular adverse event is provided be-
low, based on data from three studies (OASIS 2016; TG-MV-006
2012; TG-MV-007 2012). Although a large number of partic-
ipants were incorrectly enrolled in OASIS 2016, safety data are
presented for all participants who underwent intervention with
ocriplasmin or control treatment.
7.1. Any ocular adverse events
These were defined as any ocular adverse event that did not meet
the criteria for a serious ocular adverse event (see ’7.2. Any serious
ocular adverse events’). All four RCTs provided data for any ocular
adverse event (MIVI-IIT 2010; OASIS 2016; TG-MV-006 2012;
TG-MV-007 2012). Analysis revealed more ocular adverse events
in eyes treated with ocriplasmin compared with placebo or sham-
treated eyes (RR 1.22, 95% CI 1.09 to 1.37; 909 eyes; 4 studies;
moderate-certainty evidence; Analysis 1.6).
A breakdownof themost frequently reported ocular adverse events
is listed in the table below (n = number of eyes affected, not total
number of events). The first five ocular adverse events were par-
ticipant-reported. The most commonly reported ocular adverse
events following ocriplasmin treatment were vitreous floaters (af-
fecting 133/611 eyes or 21.8%), photopsia (affecting 98/611 eyes
or 16.0%) and injection-related eye pain (affecting 83/611 eyes or
13.6%). The incidence of vitreous floaters, photopsia, injection-
related eye pain, blurred vision and visual impairment was signif-
icantly greater in eyes treated with ocriplasmin than those treated
with sham or placebo injection.
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Study MIVI-IIT 2010 TG-MV-006 2012 TG-MV-007 2012 OASIS 2016
Ocriplas-
min
(n = 25)
Control
(n = 12)
Ocriplas-
min
(n = 220)
Control
(n = 106)
Ocriplas-
min
(n = 245)
Control
(n = 81)
Ocriplas-
min
(n = 146)
Control
(n = 74)
Any oc-
ular adverse
event
21 9 159 62 159 38 106 47
Vitreous
floatersa
- - 42 9 36 5 55 6
Photopsiaa - - 36 4 19 1 43 5
Injection-
related eye
paina
- - 33 6 30 5 20 6
Blurred vi-
siona
- - 24 4 16 2 27 4
Visual im-
pairmenta
- - 21 3 4 0 21 4
Conjuncti-
val haemor-
rhage
8 3 34 14 34 10 14 1
Increased
intraocular
pressurea
- - 9 10 9 0 10 10
Retinal teara - - 5 2 1 3 2 5
Cataracta - - 14 12 12 5 19 10
An-
terior cham-
ber cellsb
1 0 - - - - - -
Iridocyclitis
b
1 0 - - - - - -
Vitritisb 3 0 - - - - - -
aOcular adverse events not reported in MIVI-IIT.
bOcular adverse events not reported inOASIS 2016, TG-MV-006
2012, or TG-MV-007 2012.
Note: the control group in MIVI-IIT 2010 and OASIS 2016
was sham injection. The control group in TG-MV-007 2012 and
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TG-MV-006 2012 was placebo injection.
7.2. Any serious ocular adverse events
Two studies defined serious ocular adverse event as: an event re-
sulting in persistent or clinically significant disability, incapacity
or both; an event requiring inpatient hospitalisation or prolonga-
tion of an existing hospital stay; or an event that was considered to
be medically important (TG-MV-006 2012; TG-MV-007 2012).
One study did not provide a definition of a serious ocular adverse
event (OASIS 2016). MIVI-IIT 2010 reported no instances of
serious ocular adverse events.
A breakdown of the most frequently reported serious ocular ad-
verse events is listed in the table below (n = number of eyes affected,
not total number of events). The total incidence of serious ocular
adverse events was 66/611 (10.8%) in eyes treated with ocriplas-
min compared with 35/261 (13.4%) treated with sham or placebo
injection. Most frequently reported was an increased or new mac-
ular hole, which occurred in 47/611 (7.7%) of eyes treated with
ocriplasmin compared with 26/261 (9.9%) of eyes treated with
sham or placebo injection. None of the included studies reported
any cases of endophthalmitis.
Study MIVI-IIT 2010 TG-MV-006 2012 TG-MV-007 2012 OASIS 2016
Ocriplas-
min
(n = 25)
Control
(n = 12)
Ocriplas-
min
(n = 220)
Control
(n = 106)
Ocriplas-
min
(n = 245)
Control
(n = 81)
Ocriplas-
min
(n = 146)
Control
(n = 74)
Any serious
ocular ad-
verse event
0 0 21 11 15 9 30 15
Macular
hole
(increased or
new)
- - 15 11 9 5 23 10
Retinal de-
tachment
- - 2 2 0 1 1 1
Reduced vi-
sual acuity
- - 1 0 2 1 18 18
Endoph-
thalmitis
0 0 0 0 0 0 0 0
Note: the control group in MIVI-IIT 2010 and OASIS 2016
was sham injection. The control group in TG-MV-007 2012 and
TG-MV-006 2012 was placebo injection.
D I S C U S S I O N
Summary of main results
We identified four RCTs, with 932 eyes, comparing ocriplasmin
with control (placebo or sham injection) treatment. On full-text
analysis, we excluded 50 participants due to breaches of our inclu-
sion criteria, and 23 participants because they received a different
dose of ocriplasmin, giving 859 eyes for outcome analysis. The
studies were conducted in Europe and the USA. We found that
treatment with ocriplasmin increased the likelihood of complete
release of vitreous traction compared to control (sham or placebo
injection) treatment. Ocriplasmin was also associated with a 3-
line or greater improvement in BCVA and improvement in par-
ticipant-reported visual function.
There were however, more ocular adverse events in eyes treated
with ocriplasmin than control (placebo or sham injection) treat-
ment. Many of these adverse events, particularly vitreous floaters
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and photopsia, are known to be associated with posterior vitre-
ous detachment. Of the serious ocular adverse events, increased
or new macular hole was the most frequently reported. Given the
high incidence in all eyes regardless of treatment, this most likely
represents the natural history of VMT in a significant proportion
of patients.
Overall completeness and applicability of
evidence
Three of the included studies were large and contributed the ma-
jority of included participants (834) for our analysis (OASIS 2016;
TG-MV-006 2012; TG-MV-007 2012). The other study, de-
signed to determine the appropriate dose, contributed a relatively
small number (25) of participants (MIVI-IIT 2010). The control
groups in the trials also varied, with participants in TG-MV-006
2012 and TG-MV-007 2012 receiving a placebo injection, and
participants inMIVI-IIT 2010 and OASIS 2016 receiving a sham
injection. Due to the mechanical nature of the primary outcome,
the variation in control group intervention could impact on the
validity of the results, particularly adverse events. All four trials
reported the same primary outcome and follow-up periods were
identical. One trial reported additional secondary outcome data
at 24-months (OASIS 2016).
It is important to note that OASIS 2016 initially randomised and
treated 220 participants, but subsequent central reading centre
analysis revealed 50 participants were ineligible due to lack of
sVMA, presence of ERMor presence ofMHgreater than 400µm.
To comply with the inclusion and exclusion criteria of this review,
we used only data from this smaller, central reading centre verified
cohort of participants. Despite this attrition bias, sufficient pooled
data were available, hence the impact of this bias was deemed
small.
Quality of the evidence
Generally, we graded the risk of bias as low. However, two studies
reported cases that did not complete the study on the Clinical-
Trials.gov database (see Characteristics of included studies table)
but the publications did not describe these losses to follow-up
(TG-MV-006 2012; TG-MV-007 2012). The authors confirmed
using the last-observation-carried-forward (LOCF) method for
their missing outcome data, assuming the outcome was unlikely
to change after discontinuation of treatment and likely to improve
spontaneously over time. As these losses to follow-up were not
described in the original papers, we judged the risk of bias for
incomplete outcome data as unclear.
Potential biases in the review process
We followed a standard Cochrane protocol (Neffendorf 2015), to
minimise potential methodological biases in the review process.
Agreements and disagreements with other
studies or reviews
In the UK, NICE recommends the use of ocriplasmin for adults
with VMT causing severe sight problems or a MH up to 400 µm,
in the absence of ERM. Our findings support this.
Subsequent publications and postmarket surveillance studies have
addressed the safety of ocriplasmin. One large postmarket surveil-
lance study found lower rates of adverse events than were re-
ported in the registration studies, but noted that under-report-
ing is common in post-market surveillance studies (Hahn 2015).
Members of the British and Eire Association of VitreoRetinal Sur-
geons (BEAVRS) have reported their experience with ocriplasmin
in comparison to the MIVI-TRUST trial data (Haynes 2017).
They found a lower rate of MH closure and increased incidence
of adverse events with ocriplasmin compared to the registration
studies, but there is an uncertain risk of reporting bias.
Our review found a higher rate of vitreous floaters and photopsia
with ocriplasmin, but no increased risk of loss in visual acuity and
retinal detachment. There have been reports of acute reduction in
visual acuity, electroretinography changes, dyschromatopsia, pha-
codonesis and OCT ellipsoid zone alteration, but the majority
have been transient (Khan 2016; Neffendorf 2016).
Various studies and reviews have suggested certain subgroups of
sVMA participants may be more likely to respond successfully
to ocriplasmin treatment based on baseline characteristics such as
adhesion diameter, lack of coexisting ERM, and the angle between
the posterior vitreous cortex and the ILM (Haller 2015; Jackson
2016; Paul 2017). However, such analyses are exploratory, and
without confirmatory prospective RCTs they are beyond the scope
of this review.
There are different approaches to potentially manage sVMA in-
cluding PPV, intravitreal gas injection, ocriplasmin and observa-
tion. Further research, ideally in a head-to-head trial, would be
beneficial.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found evidence to support the use of ocriplasmin for the treat-
ment of symptomatic vitreomacular adhesion (sVMA), although
the number of studies was low. There are reported concerns about
the safety of ocriplasmin treatment and there is debate within the
vitreoretinal community regarding the advantages and disadvan-
tages of ocriplasmin.
Implications for research
Further large randomised controlled trials would augment our
current understanding of the safety and efficacy of ocriplasmin.
Ideally these would compare ocriplasmin with other commonly
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used management options, in particular observation or pars plana
vitrectomy. Randomised controlled trials recruiting participants
with baseline characteristics thought to improve the efficacy of
ocriplasmin are warranted.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
MIVI-IIT 2010
Methods Study design: RCT, single treated eye.
Number randomised: 60 total; 48 microplasmin; 12 sham injection.
Exclusions after randomisation: none.
Number analysed: at 28 days and 6 months; 60 total; 48 microplasmin; 12 sham
injection
Unit of analysis: eyes.
Losses to follow-up: 0 participants total.
How was missing data handled? no missing data.
Power calculation: not documented.
Participants Country: Belgium.
Mean age: 70.0 years overall; 69.9 years for ocriplasmin group; 70.0 years for sham
injection group
Gender: 33/60 (55%) women, 27/60 (45%) men total; 27/48 (56%) women, 21/48
(44%) men in microplasmin group; 6/12 (50%) women, 6/12 (50%) men in sham
injection group
Inclusion criteria: aged > 18 years; partial PVD on ultrasound examination; OCT
evidence of at least a partial attachment in the foveal area, resulting in a macular thickness
of ≥ 250 µm; BCVA ≤ 20/40 in study eye; BCVA ≥ 20/400 in fellow eye
Exclusion criteria: active PDR; highmyopia (axial length >26mm); previous vitrectomy
or uncontrolled glaucoma; previous intravitreal injections in the past 3 months in study
eye; intraocular surgery or laser photocoagulation in the past 3 months in study eye;
rhegmatogenous retinal detachment in either eye
Equivalence of baseline characteristics: no; more participants in microplasmin group
had tractional diabetic macular oedema compared with sham injection group
Interventions Intervention 1: single intravitreal injection microplasmin 125 µg.
Intervention 2: single intravitreal injection microplasmin 75 µg.
Intervention 3: single intravitreal injection microplasmin 175 µg.
Intervention 4: intravitreal injection of microplasmin 125 µg at baseline, followed by a
further microplasmin 125 µg intravitreal injection at 28 days if VMA was still present,
followed by a further microplasmin 125 µg intravitreal injection at 56 days after baseline
if VMA was still present
Comparator: sham injection (conjunctiva touched with a blunt needle by a non-masked
investigator and no injection given)
Length of follow-up: planned 180 days, actual 180 days.
As the recommended dose of ocriplasmin is 125 µg, and this is the subject of this review,
only data from the first and fourth intervention arms were analysed
Outcomes Primary outcome, as defined in study reports: “the primary outcome of this study
was total PVD induction at Day 14, as assessed by a central reading centre.”
Secondary outcomes, as defined in study reports: total PVD at other time points
assessed by the central reading centre and investigators; resolution of index condition
(VMA orMH); resolution of VMA; progression of PVD; need for vitrectomy; resolution
of macular oedema; change in BCVA; BCVA 5-, 10- and 15-letter improvement
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MIVI-IIT 2010 (Continued)
Adverse events reported: yes.
Intervals at which outcomes assessed: 3, 7, 14, 28, 90 and 180 days.
Notes Funding sources: study sponsored by ThromboGenics NV.
Study period: 2 years; 2007-2009.
Reported subgroup analyses: yes.
Full results of study were presented at EURetina 2009, Nice, France
NCT00435539.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation for the
MIVI-IIT RCT not described
Quote: “Four cohorts of 15 patients were
randomised as 4:1 to treatment or sham
injection, resulting in 12 patients receiving
microplasmin and 3 patients receiving the
sham injection in each cohort.” p. 1123
Allocation concealment (selection bias) Unclear risk Insufficient informationdocumented to as-
sess allocation concealment
Quote: “Four cohorts of 15 patients were
randomised as 4:1 to treatment or sham
injection, resulting in 12 patients receiving
microplasmin and 3 patients receiving the
sham injection in each cohort.” p. 1123
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Sham injection was performed, rather than
actual placebo injection
Quote: “In the patients receiving a sham in-
jection, microplasmin was prepared in the
same manner, but instead of an intraocu-
lar injection, the conjunctiva was touched
with a blunt needle by a nonmasked in-
vestigator and no injection was given.” p.
1123
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All patient examinations before
drug allocation and in the 6-month follow-
up period after the last injection were per-
formed by masked investigators and study
personnel.” p. 1123
“Posterior vitreous detachment status and
macular thickness were assessed by the in-
vestigator aswell as by a central reading cen-
ter (CRC), located in Munich, Germany.”
p. 1124
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MIVI-IIT 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data.
Selective reporting (reporting bias) Low risk All outcomes defined in trial registry were
reported.
Other bias Low risk
OASIS 2016
Methods Study design: RCT, single treated eye.
Number randomised: 220 total; 146 ocriplasmin; 74 sham.
Exclusions after randomisation: 50 participants subsequently deemed ineligible by
central reading centre
Number analysed: at 28 days: 168 total; 111 ocriplasmin; 59 sham.
Unit of analysis: eyes.
Losses to follow-up: 2 participants total; 1 ocriplasmin group (1 lost to follow-up); 1
sham group (1 lost to follow-up)
How was missing data handled? other than VMA release at 28 days, no data published
regarding cohort who met central reading centre eligibility criteria
Power calculation: 210 participants for at least 90% power at 2-sided alpha of 0.05
to assume a primary endpoint of 37% in ocriplasmin group and a 14% rate in placebo
group
Participants Country: USA.
Mean age: 69.1 years overall; 69.4 years for ocriplasmin group; 68.5 years for sham
group
Gender: 147/218 (67.4%) women, 71/218 (32.6%) men total; 102/145 (70.3%)
women, 43/145 (29.7%) men in ocriplasmin group; 45/73 (61.6%) women, 28/73 (38.
4%) men in sham group
Inclusion criteria: aged > 18 years; presence of VMA; BCVA ≤ 20/32 in study eye;
BCVA ≥ 20/800 in non-study eye
Exclusion criteria: history or current evidence of proliferative retinopathy, exudative
AMD or retinal vein occlusion in the study eye; people with any vitreous haemorrhage
or any other vitreous opacification which precludes either visualisation of the posterior
pole by visual inspection OR adequate assessment of the macula by OCT; MH > 400
µm in diameter in the study eye; presence of epiretinal membrane; aphakia in study eye;
high myopia (> -8 dioptres in study eye); history of rhegmatogenous retinal detachment
in either eye; prior vitrectomy in study eye; previous participation in this trial or prior
administration of ocriplasmin in study eye
Equivalence of baseline characteristics: yes.
Interventions Intervention: single intravitreal injection of ocriplasmin 125 µg in 0.10 mL volume
Comparator: sham (the same syringe hubwas pressed against the conjunctiva to simulate
an injection)
Length of follow-up: planned 24 months, actual 24 months. Data of central reading
centre approved study participants only reported at 28 days
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OASIS 2016 (Continued)
Outcomes Primary outcome, as defined in study reports: “proportion of subjects with pharma-
cological vitreomacular adhesion (VMA)/vitreomacular traction (VMT) resolution at
day 28. Pharmacological VMA resolution without anatomical defect, based on spectral
domain optical coherence tomography and determined by the masked central reading
center (CRC), with post-resolution vitrectomy considered as a failure.”
Secondary outcomes, as defined in study reports: “proportion of subjects with a ≥2
line improvement in best-corrected visual acuity (BCVA) from baseline at month 24,
irrespective of vitrectomy.”
Adverse events reported: yes.
Intervals at which outcomes assessed: 7 and 28 days; 3, 6, 9, 12, 15, 18, 21 and 24
months.
Notes Funding sources: study sponsored by ThromboGenics NV.
Study period: 3 years; 2011-2014.
Reported subgroup analyses: yes.
Additional information: large proportionof participantswere deemed eligible, recruited
and treated by investigators. Retrospective central reading centre review found 50 partic-
ipants ineligible for following reasons (MH > 400 µm, presence of epiretinal membrane
or no sVMA at baseline). Our analysis only included data reported for correctly eligible
cohort of participants
NCT01429441.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Methodof random sequence generation for
the MIVI-IIT RCT described
Quote: “Randomization was stratified on
the basis of the presence or absence of
FTMH at baseline and was centralized
through an interactive voice response sys-
tem.” p. 2233
Allocation concealment (selection bias) Low risk Method of allocation concealment for
MIVI-IIT RCT described.
Quote: “Randomization was stratified on
the basis of the presence or absence of
FTMH at baseline and was centralized
through an interactive voice response sys-
tem.” p. 2233
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Performance bias explained.
Quote: “The trial was conducted in a dou-
ble-maskedmanner. Tomaintain themask-
ing of the investigator, an unmasked inject-
ing physician was assigned to perform the
injection and access the interactive voice re-
sponse system to receive the assigned treat-
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ment. The unmasked personnel did not
perform or participate in any other trial-re-
lated procedures or assessments.” p. 2233
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Detection bias appropriately explained.
Quote: “The trial was conducted in a dou-
ble-maskedmanner. Tomaintain themask-
ing of the investigator, an unmasked inject-
ing physician was assigned to perform the
injection and access the interactive voice re-
sponse system to receive the assigned treat-
ment. The unmasked personnel did not
perform or participate in any other trial-re-
lated procedures or assessments.” p. 2233
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Large proportion of participants deemed
eligible, recruited and treated by investiga-
tors. Retrospective central reading centre
review found 50 participants ineligible for
following reasons (MH>400µm,presence
of epiretinalmembrane or no sVMA).Out-
come data for correct eligible cohort of par-
ticipants only given for primary outcome.
No secondary outcome data described
Selective reporting (reporting bias) Low risk All outcomes defined in trial registry were
reported.
Other bias Low risk No other source of bias.
TG-MV-006 2012
Methods Study design: RCT, single treated eye.
Number randomised: 326 total; 219 ocriplasmin; 107 placebo.
Exclusions after randomisation: 0.
Number analysed: at 28 days: 326 total; 219 ocriplasmin; 107 placebo. At 180 days:
298 total; 200 ocriplasmin; 98 placebo
Unit of analysis: eyes.
Losses to follow-up: 28 participants total; 19 ocriplasmin group (2 adverse event, 8
withdrawal by participants, 6 lost to follow-up, 3 death); 9 placebo group (2 adverse
event, 4 withdrawal by participants, 3 lost to follow-up)
How was missing data handled? missing data not reported in study publications.
Power calculation: 320 participants for > 90% power at 2-sided alpha of 0.05 to assume
a primary endpoint of 27.5% in ocriplasmin group and 10.0% in placebo group
Participants Country: USA.
Mean age: 71.4 years overall; 71.5 years for ocriplasmin group; 71.1 years for placebo
group
Gender: 207/326 (63.5%) women, 119/326 (36.5%) men total; 148/219 (67.6%)
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women, 71/219 (32.4%) men in ocriplasmin group; 59/107 (55.1%) women, 52/107
(48.6%) men in placebo group
Inclusion criteria: aged > 18 years; focal VMA (vitreous adhesion to macula within 6-
mm central retinal field surrounded by elevation of posterior vitreous cortex, as seen on
OCT that in the opinion of investigator was related to decreased visual function (e.g.
metamorphopsia, decreased visual acuity or other visual complaint); BCVA ≤ 20/25 in
study eye; BCVA ≥ 20/800 in non-study eye
Exclusion criteria: any evidence of proliferative retinopathy (including PDR or other
ischaemic retinopathies involving vitreoretinal vascular proliferation) or exudative AMD
or retinal vein occlusion in study eye; people with any vitreous haemorrhage or any other
vitreous opacification which precludes either: visualisation of posterior pole by visual
inspection OR adequate assessment of macula by either OCT or fluorescein angiogram
(or both) in study eye; MH > 400 µm in diameter in study eye; aphakia in study eye;
high myopia (> -8 dioptres); uncontrolled glaucoma; lenticular or zonular instability;
history of retinal detachment in either eye; prior vitrectomy or prior laser photocoag-
ulation of macula; treatment with ocular surgery, intravitreal injection or retinal laser
photocoagulation in the previous 3 months
Equivalence of baseline characteristics: no; pseudophakia more common in ocriplas-
min group than in placebo group; more women in ocriplasmin group than in placebo
group
Interventions Intervention: single intravitreal injection of ocriplasmin 125 µg in 0.10 mL volume
Comparator: single intravitreal injection of 0.10 mL placebo with identical drug vehicle
diluted with saline
Length of follow-up: planned 180 days, actual 180 days.
Outcomes Primary outcome, as defined in study reports: “the primary end point was the propor-
tion of subjects with nonsurgical resolution of vitreomacular adhesion at day 28 post-
injection, as determined by masked OCT evaluation obtained from the central reading
centre.”
Secondary outcomes, as defined in study reports: proportion of participants with total
PVD at day 28, as determined by B-scan ultrasound; need for vitrectomy; closure of
an MH; gain ≥ 3-lines BCVA without vitrectomy; change from baseline in BCVA and
VFQ-25 score at 6 months
Adverse events reported: yes.
Intervals at which outcomes assessed: 7, 14, 28, 90 and 180 days.
Notes Funding sources: study sponsored by ThromboGenics NV.
Study period: 2 years; 2008-2009.
Reported subgroup analyses: yes.
NCT00781859.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Supplementary material: “subjects will be
randomised centralized through a tele-
phone-based Interactive Voice Response
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System (IVRS) to either microplasmin in-
travitreal injection or placebo in a 3:1 al-
location ratio. Blocks of treatment will be
assigned to sites in a manner expected to
minimize the potential for imbalance in the
desired randomization ratio.” Protocol p.
17
Allocation concealment (selection bias) Low risk Supplementary material: “subjects will be
randomised centralized through a tele-
phone-based Interactive Voice Response
System (IVRS) to either microplasmin in-
travitreal injection or placebo in a 3:1 al-
location ratio. Blocks of treatment will be
assigned to sites in a manner expected to
minimize the potential for imbalance in the
desired randomization ratio.” Protocol p.
17
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patients randomly assigned to the
ocriplasmin group received an intravitreal
injection of ocriplasmin (125 µg in a 0.10-
ml volume) drawn from a vial containing
ocriplasmin into which 0.75 ml of com-
mercial saline had been injected (1875 µg
of ocriplasmin in a 0.75-ml drug vehicle).
Patients randomly assigned to placebo re-
ceived an intravitreal injection of 0.10 ml
of the identical drug vehicle diluted with
saline, the method used being the same as
that used to prepare ocriplasmin.” p. 608
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Trained readers at a central read-
ing center (Duke University OCTReading
Center, Durham, NC) who were unaware
of the group assignments evaluated the
OCT images. All ultrasonographic stud-
ies were standardized and performed by
certified technicians who underwent spe-
cial training for the study. Staging of pos-
terior vitreous detachment was based on
dynamic ultrasonographic evaluation and
performed by an investigator who was un-
aware of the group assignments.” p. 608
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Nodescription found in article, but 28 par-
ticipants reported as not completing study
on ClinicalTrials.gov. The corresponding
author of Stalmans and colleagues (2012)
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TG-MV-006 2012 (Continued)
was contacted to query this. ThromboGen-
ics NV responded by confirming use of
last observation carried forward (LOCF)
approach to input missing data for vis-
its postdiscontinuation. Their explanation
was: “use of LOCF was appropriate when
the outcome is not expected to change af-
ter discontinuation and is a conservative
method when the outcome is expected to
improve spontaneously over time. The pri-
mary endpoint, pharmacological VMA res-
olution in particular, is an outcome of that
nature.” As these losses to follow-up were
not reported in original paper, risk of attri-
tion bias was deemed unclear
Selective reporting (reporting bias) Low risk All defined outcomes in methods were re-
ported.
Other bias Unclear risk Baseline imbalance between study groups
as pseudophakia was more common in
ocriplasmin group than in placebo group
and there weremore women in ocriplasmin
group than in placebo group
TG-MV-007 2012
Methods Study design: RCT, single treated eye.
Number randomised: 326 total; 245 ocriplasmin; 81 placebo.
Exclusions after randomisation: none.
Number analysed: at 28 days: 326 total; 245 ocriplasmin; 81 placebo. At 180 days: 309
total; 235 ocriplasmin; 74 placebo
Unit of analysis: eyes.
Losses to follow-up: 17 participants total; 10 ocriplasmin group (5 withdrawal by
participant, 2 lost to follow-up, 2 adverse event, 1 death); 7 placebo group (1 physician
decision, 4 withdrawal by participant, 2 lost to follow-up)
How was missing data handled? missing data not reported in study publications.
Power calculation: 320 participants for > 90% power at 2-sided alpha of 0.05 to assume
a primary endpoint of 27.5% in ocriplasmin group and 10.0% rate in placebo group
Participants Countries: Belgium, Czech Republic, Germany, Poland, Spain, UK, USA.
Mean age: 72.0 years overall; 72.6 years for ocriplasmin group; 70.2 years for placebo
group
Gender: 222/326 (68.1%) women, 104/326 (31.9%) men total; 166/245 (67.8%)
women, 79/245 (32.2%) men in ocriplasmin group; 56/81 (69.1%) women, 25/81 (30.
9%) men in placebo group
Inclusion criteria: aged > 18 years; focal VMA (vitreous adhesion to macula within 6-
mm central retinal field surrounded by elevation of posterior vitreous cortex, as seen on
OCT that in the opinion of investigator was related to decreased visual function (e.g.
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metamorphopsia, decreased visual acuity or other visual complaint); BCVA ≤ 20/25 in
study eye; BCVA ≥ 20/800 in non-study eye
Exclusion criteria: any evidence of proliferative retinopathy (including PDR or other
ischaemic retinopathies involving vitreoretinal vascular proliferation) or exudative AMD
or retinal vein occlusion in study eye; people with any vitreous haemorrhage or any other
vitreous opacification which precludes either: visualisation of posterior pole by visual
inspection OR adequate assessment of macula by either OCT or fluorescein angiogram
(or both) in study eye; MH > 400 µm in diameter in study eye; aphakia in study eye;
high myopia (> -8 dioptres); uncontrolled glaucoma; lenticular or zonular instability;
history of retinal detachment in either eye; prior vitrectomy or prior laser photocoag-
ulation of macula; treatment with ocular surgery, intravitreal injection or retinal laser
photocoagulation in the previous 3 months
Equivalence of baseline characteristics: no; pseudophakia more common in ocriplas-
min group than in placebo group; more women in ocriplasmin group than in placebo
group
Interventions Intervention: single intravitreal injection of ocriplasmin 125 µg in 0.10 mL volume
Comparator: single intravitreal injection of 0.10 mL placebo with identical drug vehicle
diluted with saline
Length of follow-up: planned 180 days, actual 180 days.
Outcomes Primary outcome, as defined in study reports: “the primary end point was the pro-
portion of subjects with nonsurgical resolution of VMA at day 28 post-injection, as
determined by masked OCT evaluation obtained from the central reading centre.”
Secondary outcomes, as defined in study reports: proportion of participants with total
PVD at day 28, as determined by B-scan ultrasound; need for vitrectomy; closure of
an MH; gain ≥ 3-lines BCVA without vitrectomy; change from baseline in BCVA and
VFQ-25 score at 6 months
Adverse events reported: yes.
Intervals at which outcomes assessed: 7, 14, 28, 90 and 180 days.
Notes Funding sources: study sponsored by ThromboGenics NV.
Study period: 2 years; 2008-2010.
Reported subgroup analyses: yes.
NCT00798317.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Supplementary material: “subjects will be
randomised centralized through a tele-
phone-based Interactive Voice Response
System (IVRS) to either microplasmin in-
travitreal injection or placebo in a 3:1 al-
location ratio. Blocks of treatment will be
assigned to sites in a manner expected to
minimize the potential for imbalance in the
desired randomization ratio.” Protocol p.
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17
Allocation concealment (selection bias) Low risk Supplementary material: “subjects will be
randomised centralized through a tele-
phone-based Interactive Voice Response
System (IVRS) to either microplasmin in-
travitreal injection or placebo in a 3:1 al-
location ratio. Blocks of treatment will be
assigned to sites in a manner expected to
minimize the potential for imbalance in the
desired randomization ratio.” Protocol p.
17
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patients randomly assigned to the
ocriplasmin group received an intravitreal
injection of ocri- plasmin (125µg in a 0.
10-ml volume) drawn from a vial contain-
ing ocriplasmin into which 0.75ml of com-
mercial saline had been injected (1875µg
of ocriplasmin in a 0.75-ml drug vehicle).
Patients randomly assigned to placebo re-
ceived an intravitreal injection of 0.10 ml
of the identical drug vehicle diluted with
saline, the method used being the same as
that used to prepare ocriplasmin”. p. 608
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Trained readers at a central read-
ing center (Duke University OCTReading
Center, Durham, NC) who were unaware
of the group assignments evaluated the
OCT images. All ultrasonographic stud-
ies were standardized and performed by
certified technicians who underwent spe-
cial training for the study. Staging of pos-
terior vitreous detachment was based on
dynamic ultrasonographic evaluation and
performed by an investigator who was un-
aware of the group assignments.” p. 608
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Nodescription found in article, but 17 par-
ticipants reported as not completing study
on ClinicalTrials.gov. The corresponding
author of Stalmans and colleagues (2012)
was contacted to query this. ThromboGen-
ics NV responded by confirming use of
last observation carried forward (LOCF)
approach to input missing data for vis-
its postdiscontinuation. Their explanation
was: “use of LOCF was appropriate when
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the outcome is not expected to change af-
ter discontinuation and is a conservative
method when the outcome is expected to
improve spontaneously over time. The pri-
mary endpoint, pharmacological VMA res-
olution in particular, is an outcome of that
nature.” As these losses to follow-up were
not reported in original paper, risk of attri-
tion bias was deemed unclear
Selective reporting (reporting bias) Low risk All defined outcomes in methods were re-
ported.
Other bias Unclear risk Baseline imbalance between study groups
as pseudophakia was more common in
ocriplasmin group than in placebo group
and there weremore women in ocriplasmin
group than in placebo group
AMD: age-related macular degeneration; BCVA: best corrected visual acuity; FTMH: full-thickness macular hole; MH: macular
hole; OCT: optical coherence tomography; PDR: proliferative diabetic retinopathy; PVD: posterior vitreous detachment; RCT:
randomised controlled trial; sVMA: symptomatic vitreomacular adhesion; VFQ-25: Visual Function Questionnaire 25; VMA:
vitreomacular adhesion.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Benz 2010 Indication for ocriplasmin was not symptomatic vitreomacular adhesion. It was investigating whether 125 µg
microplasmin would induce vitreous release in people scheduled for PPV
De Smet 2009 Investigated safety and efficacy of 4 different doses of intravitreal microplasmin prior to preplanned PPV.
Subsequent PPV occurred either 1-2 hours, 24 hours or 7 days following ocriplasmin, meaning the participant
population and outcome measures were not eligible for inclusion in our review
Dugel 2015 Post hoc analysis of data from studies we already extracted data from (TG-MV-006 and TG-MV-007)
Elbendary 2011 Autologous plasmin injected into participants with diabetic macular oedema associated with vitreomacular
traction
Jackson 2017 Incorrect study design; post hoc analysis.
Lanzetta 2014a Postmarket surveillance study, not an RCT, therefore not eligible for inclusion
Lanzetta 2014b Post-hoc analysis of data, not an RCT, therefore excluded.
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Lescrauwaet 2016 Not an RCT.
Novack 2015 Eligible participants for this study required exudative age-related macular degeneration, which did not meet
inclusion criteria for our review
PPV: pars plana vitrectomy; RCT: randomised controlled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Ocriplasmin versus sham injection
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete release of vitreous
adhesion 28 days after
treatment
4 859 Risk Ratio (M-H, Random, 95% CI) 3.46 [2.00, 6.00]
2 Closure of macular hole 28 days
after treatment
3 229 Risk Ratio (M-H, Random, 95% CI) 2.87 [1.50, 5.51]
3 Complete posterior vitreous
detachment 28 days after
treatment
3 689 Risk Ratio (M-H, Random, 95% CI) 2.94 [1.39, 6.24]
4 > 3-line improvement in BCVA
6 months after treatment
3 674 Risk Ratio (M-H, Random, 95% CI) 1.95 [1.07, 3.53]
5 Requirement for pars plana
vitrectomy at month 6
3 689 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.50, 0.91]
6 Any ocular adverse event 4 909 Risk Ratio (M-H, Random, 95% CI) 1.22 [1.09, 1.37]
Analysis 1.1. Comparison 1 Ocriplasmin versus sham injection, Outcome 1 Complete release of vitreous
adhesion 28 days after treatment.
Review: Ocriplasmin for symptomatic vitreomacular adhesion
Comparison: 1 Ocriplasmin versus sham injection
Outcome: 1 Complete release of vitreous adhesion 28 days after treatment
Study or subgroup Ocriplasmin Sham Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
MIVI-IIT 2010 (1) 11/25 1/12 7.3 % 5.28 [ 0.77, 36.30 ]
OASIS 2016 54/111 5/59 25.7 % 5.74 [ 2.43, 13.57 ]
TG-MV-006 2012 (2) 61/219 14/107 41.9 % 2.13 [ 1.25, 3.63 ]
TG-MV-007 2012 (3) 62/245 5/81 25.1 % 4.10 [ 1.71, 9.84 ]
Total (95% CI) 600 259 100.0 % 3.46 [ 2.00, 6.00 ]
Total events: 188 (Ocriplasmin), 25 (Sham)
Heterogeneity: Tau2 = 0.11; Chi2 = 4.74, df = 3 (P = 0.19); I2 =37%
Test for overall effect: Z = 4.42 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours sham or placebo Favours ocriplasmin
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(1) ”Resolution of vitreomacular adhesion”, day 28
(2) ”Resolution of vitreomacular adhesion”, day 28
(3) ”Resolution of vitreomacular adhesion”, day 28
Analysis 1.2. Comparison 1 Ocriplasmin versus sham injection, Outcome 2 Closure of macular hole 28 days
after treatment.
Review: Ocriplasmin for symptomatic vitreomacular adhesion
Comparison: 1 Ocriplasmin versus sham injection
Outcome: 2 Closure of macular hole 28 days after treatment
Study or subgroup Ocriplasmin Sham Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
OASIS 2016 15/50 4/26 42.8 % 1.95 [ 0.72, 5.28 ]
TG-MV-006 2012 25/57 4/32 45.8 % 3.51 [ 1.34, 9.19 ]
TG-MV-007 2012 18/49 1/15 11.4 % 5.51 [ 0.80, 37.92 ]
Total (95% CI) 156 73 100.0 % 2.87 [ 1.50, 5.51 ]
Total events: 58 (Ocriplasmin), 9 (Sham)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours sham or placebo Favours ocriplasmin
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Analysis 1.3. Comparison 1 Ocriplasmin versus sham injection, Outcome 3 Complete posterior vitreous
detachment 28 days after treatment.
Review: Ocriplasmin for symptomatic vitreomacular adhesion
Comparison: 1 Ocriplasmin versus sham injection
Outcome: 3 Complete posterior vitreous detachment 28 days after treatment
Study or subgroup Ocriplasmin Sham Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
MIVI-IIT 2010 6/25 1/12 13.7 % 2.88 [ 0.39, 21.32 ]
TG-MV-006 2012 36/219 7/107 79.1 % 2.51 [ 1.16, 5.46 ]
TG-MV-007 2012 26/245 0/81 7.2 % 17.67 [ 1.09, 286.67 ]
Total (95% CI) 489 200 100.0 % 2.94 [ 1.39, 6.24 ]
Total events: 68 (Ocriplasmin), 8 (Sham)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.07, df = 2 (P = 0.35); I2 =3%
Test for overall effect: Z = 2.82 (P = 0.0048)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours ocriplasmin Favours sham or placebo
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Analysis 1.4. Comparison 1 Ocriplasmin versus sham injection, Outcome 4 > 3-line improvement in BCVA
6 months after treatment.
Review: Ocriplasmin for symptomatic vitreomacular adhesion
Comparison: 1 Ocriplasmin versus sham injection
Outcome: 4 > 3-line improvement in BCVA 6 months after treatment
Study or subgroup Ocriplasmin Sham Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
MIVI-IIT 2010 3/13 0/9 4.4 % 5.00 [ 0.29, 86.43 ]
TG-MV-006 2012 28/219 9/107 69.4 % 1.52 [ 0.74, 3.11 ]
TG-MV-007 2012 29/245 3/81 26.2 % 3.20 [ 1.00, 10.21 ]
Total (95% CI) 477 197 100.0 % 1.95 [ 1.07, 3.53 ]
Total events: 60 (Ocriplasmin), 12 (Sham)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.63, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.19 (P = 0.028)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours sham or placebo Favours ocriplasmin
39Ocriplasmin for symptomatic vitreomacular adhesion (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 Ocriplasmin versus sham injection, Outcome 5 Requirement for pars plana
vitrectomy at month 6.
Review: Ocriplasmin for symptomatic vitreomacular adhesion
Comparison: 1 Ocriplasmin versus sham injection
Outcome: 5 Requirement for pars plana vitrectomy at month 6
Study or subgroup Ocriplasmin Sham Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
MIVI-IIT 2010 3/25 3/12 4.4 % 0.48 [ 0.11, 2.04 ]
TG-MV-006 2012 45/219 31/107 58.3 % 0.71 [ 0.48, 1.05 ]
TG-MV-007 2012 37/245 19/81 37.4 % 0.64 [ 0.39, 1.05 ]
Total (95% CI) 489 200 100.0 % 0.67 [ 0.50, 0.91 ]
Total events: 85 (Ocriplasmin), 53 (Sham)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 2 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 2.58 (P = 0.0099)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours ocriplasmin Favours sham or placebo
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Analysis 1.6. Comparison 1 Ocriplasmin versus sham injection, Outcome 6 Any ocular adverse event.
Review: Ocriplasmin for symptomatic vitreomacular adhesion
Comparison: 1 Ocriplasmin versus sham injection
Outcome: 6 Any ocular adverse event
Study or subgroup Ocriplasmin Sham Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
MIVI-IIT 2010 21/25 9/12 9.3 % 1.12 [ 0.77, 1.62 ]
OASIS 2016 106/146 47/74 31.7 % 1.14 [ 0.94, 1.40 ]
TG-MV-006 2012 159/220 62/106 38.8 % 1.24 [ 1.03, 1.48 ]
TG-MV-007 2012 159/245 38/81 20.3 % 1.38 [ 1.08, 1.78 ]
Total (95% CI) 636 273 100.0 % 1.22 [ 1.09, 1.37 ]
Total events: 445 (Ocriplasmin), 156 (Sham)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.68, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 3.51 (P = 0.00045)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours ocriplasmin Favours sham or placebo
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Vitreous Body] this term only
#2 MeSH descriptor: [Vitreous Detachment] this term only
#3 MeSH descriptor: [Retinal Perforations] this term only
#4 MeSH descriptor: [Tissue Adhesions] this term only
#5 vitreomacular near/3 (adhesion* or traction*)
#6 VMA* or VMT*
#7 macula* near/2 hole*
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
#9 MeSH descriptor: [Fibrinolysin] this term only
#10 MeSH descriptor: [Fibrinolytic Agents] this term only
#11 MeSH descriptor: [Proteolysis] this term only
#12 MeSH descriptor: [Peptide Fragments] this term only
#13 ocriplasmin* or Jetrea* or Microplasmin*
#14 #9 or #10 or #11 or #12 or #13
#15 #8 and #14
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Appendix 2. MEDLINE Ovid search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. Vitreous Body/
14. Vitreous Detachment/
15. Retinal Perforations/
16. Tissue Adhesions/
17. (vitreomacular adj3 (adhesion$ or traction$)).tw.
18. (VMA$ or VMT$).tw.
19. (macula$ adj2 hole$).tw.
20. or/13-19
21. Fibrinolysin/
22. Fibrinolytic Agents/
23. Proteolysis/
24. Peptide Fragments/
25. (ocriplasmin$ or Jetrea$ or Microplasmin$).tw.
26. or/21-25
27. 20 and 26
28. 12 and 27
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. Embase Ovid search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
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20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. vitreous body detachment/
34. vitreous disease/
35. retina tear/
36. tissue adhesion/
37. (vitreomacular adj3 (adhesion$ or traction$)).tw.
38. (VMA$ or VMT$).tw.
39. (macula$ adj2 hole$).tw.
40. or/33-39
41. ocriplasmin/
42. fibrinolytic agent/
43. peptide fragment/
44. (ocriplasmin$ or Jetrea$ or Microplasmin$).tw.
45. or/41-44
46. 40 and 45
47. 32 and 46
Appendix 4. PubMed search strategy
(((vitreous body[MeSH Terms]) OR (vitreous detachment[MeSH Terms]) OR (Retinal Perforations[MeSH Terms]) OR (tissue adhe-
sions[MeSH Terms]) OR (vitreomacular adhesion*[Text Word]) OR (vitreomacular traction*[Text Word]) OR (VMA*[Text Word]
OR VMT*[Text Word]) OR (macula* AND hole*[Text Word])) AND ((fibrinolysin[MeSH Terms]) OR (fibrinolytic agents[MeSH
Terms]) OR (proteolysis[MeSHTerms]) OR (peptide fragments[MeSH Terms]) OR (ocriplasmin*[Text Word] OR Jetrea*[TextWord]
OR Microplasmin*[Text Word]))) AND (((randomized controlled trial[Publication Type]) OR (controlled clinical trial[Publication
Type]) OR (random*[Text Word] OR placebo*[Text Word] OR trial*[Text Word] OR group*[Text Word])) AND (Medline[sb]))
Appendix 5. ISRCTN search strategy
Ocriplasmin OR Jetrea OR Microplasmin
Appendix 6. ClinicalTrials.gov search strategy
(vitreomacular adhesion OR vitreomacular traction OR macular hole) AND (Ocriplasmin OR Jetrea OR Microplasmin)
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Appendix 7. WHO ICTRP search strategy
vitreomacular adhesion OR vitreomacular traction OR macular hole = Intervention AND Ocriplasmin OR Jetrea OR Microplasmin
= Condition
Appendix 8. Data on study characteristics
Mandatory items Optional items
Methods
Study design • Parallel group RCT i.e. people
randomised to treatment
• Within-person RCT i.e. eyes
randomised to treatment
• Cluster RCT i.e. communities
randomised to treatment
• Cross-over RCT
• Other, specify
Exclusions after randomisation
Losses to follow-up
Number randomised/analysed
How were missing data handled? e.g. avail-
able case analysis, imputation methods
Reported power calculation (Y/N), if yes,
sample size and power
Unusual study design/issues
Eyes or
Unit of randomisation/unit of analysis
• 1 eye included in study, specify how
eye selected
• 2 eyes included in study, both eyes
received same treatment, briefly specify how
analysed (best/worst/mean/both and adjusted
for within-person correlation/both and not
adjusted for within-person correlation) and
specify if mixture 1 eye and 2 eyes
• 2 eyes included in study, eyes
received different treatments, specify if
correct pair-matched analysis done
Participants
Country Setting
Ethnic group
Equivalence of baseline characteristics (Y/
N)
Total number of participants This information should be collected for total
study population recruited into the study. If
these data are only reported for the people who
were followed up only, please indicate.
Number (%) of men and women
Mean age and age range
Inclusion criteria
Exclusion criteria
Interventions
Intervention (n = )
Comparator (n = )
• Number of people randomised to
this group
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(Continued)
See MECIR 65 and 70
• Drug (or intervention) name
• Dose
• Frequency
• Route of administration
Outcomes
Primary and secondary outcomes as defined
in study reports
See MECIR R70
List outcomes
Adverse events reported (Y/N)
Length of follow-up and intervals at which
outcomes assessed
Planned/actual length of follow-up
Notes
Date conducted Specify dates of recruitment of participants
mm/yr to mm/yr
Full study name:(if applicable)
Reported subgroup analyses (Y/N)
Were trial investigators contacted?
Sources of funding
Declaration of interest
See MECIR 69
MECIR: Methodological expectations for Cochrane Intervention Reviews; mm: month; n: number of participants; RCT: randomised
controlled trial; yr: year.
Appendix 9. Glossary of abbreviations
BCVA: best corrected visual acuity.
BEAVRS: British and Eire vitreoretinal surgeons.
ERM: epiretinal membrane.
ETDRS: Early Treatment Diabetic Retinopathy Study.
GRADE: Grading of Recommendations, Assessment, Development and Evaluation working group.
ILM: internal limiting membrane.
logMAR: logarithm of the minimum angle of resolution.
MH: macular hole.
NEI-VFQ 25: National Eye Institute Visual Function Questionnaire - 25.
NICE: National Institute for Health and Care Excellence.
OCT: optical coherence tomography.
PVD: posterior vitreous detachment.
RCT: randomised controlled trial.
sVMA: symptomatic vitreomacular adhesion.
VFQ: Visual Function Questionnaire.
VMA: vitreomacular adhesion.
VMT: vitreomacular traction.
WHO: World Health Organization.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Due to the reporting of BCVA in the included studies, we changed our secondary outcome measure from “mean change in BCVA” to
“proportion gaining 3-line or greater improvement in VA, measured using the ETDRS scale”.
We added a secondary outcome measure, the requirement of PPV. This gives a good measure of how successful the intervention of
ocriplasmin has been (i.e. conventional treatment for sVMA has been PPV, and indeed this remains the treatment modality of choice
who fail ocriplasmin therapy).
We added information regarding “other bias” that could not be accurately categorised under the other categories of bias.
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